Can anti-TNF agents protect against rheumatoid arthritis-associated work disability?

International Journal of Clinical Rheumatology

Volumn 4, Issue 5, 2009, Pages 523-531

  Vlieland, Theodora P M Vliet ^a   van den Hout, Wilbert B ^a   de Buck, Petronella D M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adalimumab; Economic evaluation; Employment; Etanercept; Infliximab; Productivity costs; Rheumatoid arthritis; TNF antagonist; Work disability

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ABSENTEEISM; ARTICLE; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; EMPLOYMENT STATUS; FATIGUE; FUNCTIONAL DISEASE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; JOB PERFORMANCE; JOB STRESS; MEDICAL LEAVE; MONOTHERAPY; OSTEOARTHRITIS; PHYSICAL PERFORMANCE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SOCIOECONOMICS; UNEMPLOYMENT; WORK DISABILITY; WORK RESUMPTION;

EID: 71249118233     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.44     Document Type: Article

References (45)

1. Yelin E: Work disability in rheumatic diseases. Curr. Opin. Rheumatol. 19, 91-96 (2007).
2. Fautrel B, Guillemin F: Cost of illness studies in rheumatic diseases. Curr. Opin. Rheumatol. 14, 121-126 (2002).
3. Allaire SH: Update on work disability in rheumatic diseases. Curr. Opin. Rheumatol. 13, 93-98 (2001).
4. Allaire S, Wolfe F, Niu J, Lavalley MP: Contempory prevalence and incidence of work disability associated with rheumatoid arthritis. Arthritis Rheum. 59, 474-480 (2008).
5. Eberhardt K, Larsson BM, Nived K, Lindqvist E: Work disability in rheumatoid arthritis - development over 15 years and evaluation of predictive factors over time. J. Rheumatol. 34, 481-487 (2007).
6. Sokka T: Work disability in early rheumatoid arthritis. Clin. Exp. Rheumatol. 21, (5 Suppl. 31), S71-S74 (2003).
7. Verstappen SM, Bijlsma JW, Verkleij H et al.: Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum. 51, 488-497 (2004).
8. De Croon EM, Sluiter JK, Dijkmans BAC, Lankhorst GJ, Frings-Dresen MHW: Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 63, 1362-1367 (2004).
9. Allaire S, Wolfe F, Niu J, LaValley MP, Zhang B, Reisine S: Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort. Arthritis Rheum. 61, 321-328 (2009).
10. Burton W, Morrison A, Maclean R, Ruderman E: Systematic review of studies on productivity loss due to rheumatoid arthritis. Occup. Med. 56, 18-27 (2006).
11. Zirkzee EJ, Sneep AC, de Buck PD et al.: Sick leave and work disability in patients with early arthritis. Clin. Rheumatol. 27, 11-19 (2008).
12. Geuskens GA, Hazes JMW, Barendregt PJ, Burdorf A: Work and sick leave among patients with early inflammatory conditions. Arthritis Rheum. 59, 1458-1466 (2008).
13. Hammond A: Rehabilitation in musculoskeletal diseases. Best Pract. Res. Clin. Rheumatol. 22, 435-449 (2008).
14. Allaire SH: What work changes do people with arthritis make to preserve employment, and are such changes effective? Arthritis Rheum. 51, 909-916 (2004).
15. Gignac MAM, Sutton D, Badley EM: Arthritis symptoms, the work environment, and the future: measuring perceived job strain among employed persons with arthritis. Arthritis Rheum. 57, 738-747 (2007).
16. Lacaille D, White MA, Backman CL, Gignac MAM: Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum. 57, 1269-1279 (2007).
17. Macedo A, Oakley S, Gullick N, Kirkham B: An examination of work instability, functional impairment, and disease activity in employed patients with rheumatoid arthritis. J. Rheumatol. 36, 225-230 (2009).
18. Gilworth G, Chamberlain MA, Harvey A et al.: Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum. 49, 349-354 (2003).
19. Gilworth G, Emery P, Gossec L et al.: Adaptation and cross-cultural validation of the RA-WIS (Work Instability Scale). Ann. Rheum. Dis. (2008) (Epub ahead of print).
20. Puolakka K, Kautiainen H, Möttönen T et al.: Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis. A five-year randomized followup trial. Arthritis Rheum. 50, 55-62 (2004).
21. Puolakka K, Kautiainen H, Möttönen T et al.: Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann. Rheum. Dis. 64, 130-133 (2005).
22. Verstappen SMM, Jacobs JWG, Hyrich KL: Effect of anti-tumor necrosis factor on work disability. J. Rheumatol. 34, 2126-2128 (2007).
23. Kavanaugh A: Economic issues with new rheumatologic therapeutics. Curr. Opin. Rheumatol. 19, 272-276 (2007).
24. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L: Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 48, 3046-3054 (2003).
25. Smolen JS, Han C, van der Heijde D et al.: Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 54, 716-722 (2006).
26. Laas K, Peltomaa R, Kautiainen H. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann. Rheum. Dis. 65, 924-928 (2006).
27. Farahani P, Levine M, Gaebel K, Wang ECY, Khalidi N: Community-based evaluation of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 33, 665-670 (2006).
28. Wolfe F, Allaire S, Michaud K: The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J. Rheumatol. 34, 2211-2217 (2007).
29. Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M: Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum. 59, 1082-1089 (2008).
30. Bejarano V, Quinn M, Gonaghan PG et al.: Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 59, 1467-1474 (2008).
31. Halpern MT, Cifaldi MA, Kvien TK: Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann. Rheum. Dis. 68(6), 930-937 (2008).
32. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF et al.: Cost-utility ana lysis of treatment strategies in patients with recent onset rheumatoid arthritis. Arthritis Rheum. 61, 291-299 (2009).
33. Hoving JL, Bartelds GM, Sluiter JK et al.: Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand. J. Rheumatol. (2009) (Epub ahead of print).
34. Wong JB, Sing G, Kavanaugh A: Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400-408 (2002).
35. Choi HK, Seeger JD, Kuntz KM: A cost effectiveness ana lysis of treatment options for methotrexate-naive rheumatoid arthritis. J. Rheumatol. 29, 1156-1165 (2002).
36. Kobelt G, Jonsson L, Young A, Eberhardt K: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 42, 326-335 (2003).
37. Brennan A, Bansback N, Reynolds A, Conway P: Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 43, 62-72 (2004).
38. Puolakka K, Kautiainen H, Mottonen T et al.: Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis. Scand. J. Rheumatol. 38, 96-103 (2009).
39. Tanno M, Nakamura I, Ito K et al.: Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod. Rheumatol. 16, 77-84 (2006).
40. Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M: Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature. Expert Opin. Pharmcother. 10(2), 255-269 (2009).
41. Puolakka K, Kautianinen H, Möttönen T et al.: Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 52, 36-41 (2005).
42. Kanavos P, Trueman P, Bosilevac A: Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom. Int. J. Technol. Assess. Health Care 16, 1179-1192 (2000).
43. van den Hout WB: Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA. Nat. Clin. Pract. Rheumatol. 5, 78-79 (2009).
44. Bansback N, Marra CA: Now that we know what's BeSt, what is good value for the money? Arthritis Rheum. 61, 289-290 (2009).
45. Vliet Vlieland TP, De Buck PD, van den Hout WB: Vocational rehabilitation programs for individuals with chronic arthritis. Curr. Opin. Rheumatol. 21, 183-188 (2009).